Medicare Enrolled
Dr. Subrahmanya Bhat, MD
Pulmonary Disease · Stockbridge, GA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Bhat from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Bhat?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Bhat
Dr. Subrahmanya Bhat is a pulmonary disease specialist in Stockbridge, GA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Bhat performed 3,176 Medicare services across 1,286 unique beneficiaries.
Between the years covered by Open Payments, Dr. Bhat received a total of $3,798 from 43 pharmaceutical and/or device companies across 231 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Bhat is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 7% volume in GA
$3,798 industry payments
Medicare Practice Summary
Medicare Utilization ↗3,176
Medicare services
Top 7% in GA for pulmonary disease
1,286
Unique beneficiaries
$36
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~167 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
670 | $89 | $175 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
592 | $0 | $50 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
374 | $65 | $137 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
246 | $11 | $45 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
176 | $1 | $39 |
| Spirometry test A test that measures the amount of air you can exhale and how fast you can blow it out. The provider evaluates the results to check lung function. |
140 | $18 | $110 |
| Spirometry test before and after medication A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication. |
140 | $28 | $140 |
| Lung volume test using gas dilution or washout A test that measures the amount of air in your lungs by using a gas dilution or washout method. |
140 | $32 | $95 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
140 | $42 | $140 |
| Lung volume measurement test A test that measures the largest amount of air you can breathe in and out. It evaluates the total capacity of your lungs. |
138 | $11 | $90 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
114 | $8 | $32 |
| Chest X-ray, 2 views An X-ray imaging test of the chest that captures two different angles to visualize the lungs, heart, and chest wall. |
74 | $23 | $200 |
| Quadrivalent influenza vaccine, cell culture-derived A flu shot that protects against four strains of the influenza virus. It is produced using cell culture technology rather than traditional egg-based methods. |
70 | $31 | $60 |
| Flu vaccine administration This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient. |
70 | $30 | $35 |
| Drug test with direct observation A drug screening test performed under direct observation to ensure the sample is provided correctly. This method is used to verify the integrity of the specimen collection process. |
49 | $12 | $59 |
| Urinalysis, manual A manual laboratory examination of a urine sample to check for various substances and cells. |
17 | $3 | $45 |
| Chest X-ray, 1 view An X-ray image of the chest taken from a single angle. This imaging test is used to visualize the structures within the chest cavity. |
14 | $19 | $105 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
12 | $109 | $300 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$3,798
Total received (2018-2024)
Avg $543/year across 7 years
Top 40% in GA for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
43
Companies
231
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,661 (96.4%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$138 (3.6%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$355
2023
$377
2022
$380
2021
$392
2020
$616
2019
$972
2018
$707
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
ABBVIE INC.
$66
GlaxoSmithKline, LLC.
$49
SCILEX PHARMACEUTICALS INC.
$47
Amgen Inc.
$32
UCB, Inc.
$24
GENZYME CORPORATION
$23
Regeneron Healthcare Solutions, Inc.
$21
Mylan Specialty L.P.
$21
Janssen Biotech, Inc.
$21
E.R. Squibb & Sons, L.L.C.
$20
AstraZeneca Pharmaceuticals LP
$18
ANI Pharmaceuticals, Inc.
$14
Top 3 companies account for 45.6% of 2024 payments
All-time payments by company (2018-2024) ›
Sunovion Pharmaceuticals Inc.
$779
GlaxoSmithKline, LLC.
$630
AstraZeneca Pharmaceuticals LP
$356
UCB, Inc.
$311
Mylan Specialty L.P.
$237
Astellas Pharma US Inc
$179
Amgen Inc.
$142
Novo Nordisk Inc
$99
Janssen Biotech, Inc.
$92
Boehringer Ingelheim Pharmaceuticals, Inc.
$92
ABBVIE INC.
$79
AbbVie Inc.
$65
Lilly USA, LLC
$59
Kaleo, Inc.
$53
SCILEX PHARMACEUTICALS INC.
$47
Hikma Pharmaceuticals USA
$40
E.R. Squibb & Sons, L.L.C.
$38
West-Ward Pharmaceuticals
$38
Aurinia Pharma U.S., Inc.
$28
Sobi, Inc
$25
Horizon Therapeutics plc
$24
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$23
Edwards Lifesciences Corporation
$23
GENZYME CORPORATION
$23
Masimo Corporation
$22
Regeneron Healthcare Solutions, Inc.
$21
Novartis Pharmaceuticals Corporation
$21
Alexion Pharmaceuticals, Inc.
$20
Shire North American Group Inc
$20
AbbVie, Inc.
$20
Circassia Pharmaceuticals Inc
$19
Orexo US, Inc.
$17
Ironwood Pharmaceuticals, Inc
$17
Merck Sharp & Dohme Corporation
$15
ARBOR PHARMACEUTICALS, INC.
$15
Inogen, Inc.
$15
Takeda Pharmaceuticals U.S.A., Inc.
$15
ANI Pharmaceuticals, Inc.
$14
Purdue Pharma L.P.
$14
Alkermes, Inc.
$14
PFIZER INC.
$13
Eisai Inc.
$11
Horizon Pharma plc
$11
Top 3 companies account for 46.5% of all-time payments
Associated products mentioned in payments ›
ANORO · ANORO ELLIPTA · AREXVY · BENLYSTA · BEVESPI AEROSPHERE · BREZTRI · BREZTRI AEROSPHERE · BROVANA · Bimzelx · Cimzia · DUPIXENT · DUZALLO · Dayvigo · Dymista · EMMA and ISA · ENTRESTO · EVENITY · EVZIO · Edwards SAPIEN 3 Ultra Transcatheter Heart Valve · Enbrel · FARXIGA · FASENRA · FORTEO · GLASSIA · Horizant · Humira · INFLECTRA · InogenOne · KRYSTEXXA · Kineret · LONHALA MAGNAIR · LUPKYNIS · MOUNJARO · MYRBETRIQ · Mitigare · NIOX VERO · NUCALA · OFEV · ORENCIA · Otezla · Ozempic · PURIFIED CORTROPHIN GEL · Perforomist · Prolia · RAYOS · REMICADE · RENFLEXIS · RINVOQ · Rybelsus · SIMPONI ARIA · STIOLTO RESPIMAT · SYMBICORT · SYMPROIC · Strensiq · TALTZ · TAVNEOS · TRELEGY ELLIPTA · TREMFYA · TRULICITY · Trintellix · UTIBRON NEOHALER · Utibron · VRAYLAR · Vivitrol 380 mg · XIFAXAN · YUPELRI · Yupelri · ZTLido · Zubsolv
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (96%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Pulmonary diseases within 10 mi
95
Per 100K population
38.7
County median income
$81,612
Nearest hospital
PIEDMONT HENRY HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Bhat is a clinical cardiology specialist, with above-average Medicare volume (top 7% in GA), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Bhat experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Bhat performed 670 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Bhat receive payments from pharmaceutical companies?
Yes. Dr. Bhat received a total of $3,798 from 43 companies across 231 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Bhat's costs compare to other pulmonary diseases in Stockbridge?
Dr. Bhat's average Medicare payment per service is $36. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Bhat) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Stockbridge
Browse pulmonary diseases in Stockbridge ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in GA
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in GA
Which GA pulmonary diseases receive the most from drug and device companies.
By company
Sunovion Pharmaceuticals Inc. Payments to Doctors
See all physicians who received payments from Sunovion Pharmaceuticals Inc.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology